Concorde Financial’s Boston Scientific BSX Stock Holding History

Concorde Financial’s Portfolio BSX Stock Details BSX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-781	Closed	-$34K	–	72
2021 Q4	$34K	Buy	+781	New	+$32.8K	0.02%	59

Other funds holding BSX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Bollard Group Boston, Massachusetts $3.39B AUM 1.06% 1-Year Est. Return

Concorde Financial's BSX Position: Q1 2022 in Review

Concorde Financial sold out of Boston Scientific (BSX) in Q1 2022, closing a stake of 781 shares — an estimated $34K sold.

Concorde Financial first reported a position in BSX in Q4 2021 and held it in 1 quarter. The position peaked at $34K in Q4 2021. 904 funds tracked by Wall St. Rank hold BSX as of Q1 2022.

Concorde Financial reported no remaining Boston Scientific position as of Q1 2022 after selling out during the quarter.
Concorde Financial sold 781 Boston Scientific shares in Q1 2022, an estimated $34K.
Concorde Financial first reported a position in Boston Scientific in Q4 2021 and held it in 1 quarter.
Concorde Financial's Boston Scientific position peaked at $34K in Q4 2021.
904 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2022.

Based on Concorde Financial's 13F filing for Q1 2022, filed 16 May 2022.